期刊文献+

单羰基姜黄素衍生物的合成、晶体结构、体外抗菌及抗肿瘤活性研究 被引量:10

Synthesis,Crystal Structure,Antibacterial and Anti-tumor Properties of Mono-carbonyl Analogues of Curcumin
原文传递
导出
摘要 以姜黄素为先导化合物合成了两个对称的单羰基姜黄素类似物和五个查尔酮类单羰基姜黄素类似物,结构经IR,1HNMR及ESI-MS确认,用11种临床常用耐药株对其进行了体外抗菌活性筛选,同时采用MTT法测定了它们对3种人体肿瘤细胞株的细胞毒活性.其中化合物A5的体外抗肿瘤活性与姜黄素相当,并且A5对部分临床耐药菌也有一定的抑菌活性.通过单晶培养得到了A5的晶体结构,经测定表明其结构属于正交晶系,空间群Fdd2.晶胞参数a=26.085(3),b=28.248(3),c=7.9615(9),α=90.00°,β=90.00°,γ=90.00°,V=5866.4(12)3,Z=16,DX=1.288Mg/m3,μ=0.09mm-1,F(000)=324,最终偏离因子R=0.047,wR=0.112. Two symmetry and five asymmetry mono-carbonyl analogues were synthesized with curcumin as leading compound.Their structures were characterized by IR,MS and ^1H NMR techiniques.Their antibacterial activities in vitro were tested using 11 drug-resistant strains isolated in clinical.The cytotoxicity activities in vitro were evaluated by MTT assay using 3 human cancer cell lines.Compound A5 exhibited a comparable antitumor activity with curcumin and showed high antibacterial activity.Due to the good bioactivities,single-crystal of A5 was cultured and its structure was determined using single-crystal X-ray diffraction.The crystal structure of compound A5 is orthorhombic system,space group Fdd2,with cell dimensions of a=26.085(3)A°,b=28.248(3)A°,c=7.9615(9)A°,α=90.00°,β=90.00°,γ=90.00°,V=5866.4(12)A°^3,Z=16,DX=1.288 Mg/m3,μ=0.09 mm^-1,F(000)=324,The final R=0.047,wR=0.112.
出处 《有机化学》 SCIE CAS CSCD 北大核心 2010年第6期884-889,共6页 Chinese Journal of Organic Chemistry
基金 国家自然科学基金(No.20802054) 浙江省教育厅(No.20070992) 温州市科技局(No.Y20080016)资助项目
关键词 单羰基姜黄素衍生物 查尔酮 合成 抗肿瘤 抗菌活性 晶体结构 mono-carbonyl curcumin analogue chalcone synthesis anti-tumor antibacterial activity crystal structure
  • 相关文献

参考文献26

  • 1Anand,P.; Thomas,S.G.; Kunnumakkara,A.B.; Sundaram,C.; Harikumar,K.B.; Sung,B.; Tharakan,S.T.;Misra,K.; Priyadarsini,I.K.; Rajasekharan,K.N.; Aggarwal,B.B.Biochem.Pharmacol.2008,76,1590.
  • 2Maheshwari,R.K.; Singh,A.K.; Gaddipati,J.; Srimal,R.C.Life Sci.2006,78,2081.
  • 3Anand,P.; Kunnumakkara,A.B.; Newman,R.A.; Aggarwal,B.B.Mol.Pharmacol.2007,4,807.
  • 4Kunnumakkara,A.B.; Anand,P.; Aggarwal,B.B.Cancer Lett.2008,269,199.
  • 5Egan,M.E.; Pearson,M.; Weiner,S.A.; Rajendran,V.;Rubin,D.; Glockner-Pagel,J.; Canny,S.; Du,K.; Lukacs,G.L.; Caplan,M.J.Science 2004,304,600.
  • 6Hsu,C.H.; Cheng,A.L.Adv.Exp.Med.Biol.2007,595,471.
  • 7Rai,D.; Singh,J.K.; Roy,N.; Panda,D.Biochem.J.2008,410,147.
  • 8Li,X.K.; Liang,G.; Xiao,J.; Huang,Z.F.; Zhou,H.P.FASEB J.2008,22,720.
  • 9Liang,G.; Yang,S.L.; Jiang,L.J.; Zhao,Y.; Shao,L.L.;Xiao,J.; Ye,F.Q.; Li,Y.R.; Li,X.K.Chem.Pharm.Bull.2008,56,162.
  • 10Kamat,A.M.; Tharakan,S.T.; Sung,B.; Aggarwal,B.B.Cancer Res.2009,69,8958.

同被引文献120

引证文献10

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部